Product Description
Ki-67 may be considered as a valuable biomarker in breast cancer patients.
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Non-Small-Cell Lung Cancer
Phase 2: Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NeoTAILOR | P2 |
Recruiting |
Breast Cancer |
2027-11-30 |
|
| I-share | N/A |
Recruiting |
Cervical Cancer|Uterine Cancer |
2027-02-01 |
|
| ChiCTR2400079698 | N/A |
Not yet recruiting |
Breast Cancer |
2026-12-31 |
|
| MORE-T | P2 |
Active, not recruiting |
Breast Cancer |
2024-12-31 |